Core Insights - Tyra Biosciences, Inc. announced the acceptance of two abstracts for presentation at the 2026 ASCO Genitourinary Cancers Symposium, highlighting its focus on FGFR biology and precision medicine development [1] Group 1: Presentation Details - The first presentation is titled "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial," scheduled for February 27, 2026, from 11:30 AM to 12:45 PM PST [1] - The second presentation is a phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302), also on February 27, 2026, from 11:30 AM to 12:45 PM PST [1] Group 2: Company Overview - Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology, with a proprietary platform called SNÃ…P for rapid drug design [1] - The company has a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions, including oral dabogratinib, a potential first-in-class selective FGFR3 inhibitor [1] - Current planned clinical development includes three Phase 2 studies: SURF303 for low-grade upper tract urothelial carcinoma, SURF302 for intermediate risk non-muscle invasive bladder cancer, and BEACH301 for pediatric achondroplasia [1]

Core Insights - Tyra Biosciences has initiated the BEACH301 Phase 2 clinical study for dabogratinib, the only oral FGFR3-selective inhibitor in development for achondroplasia, marking a significant milestone in the treatment of this condition [1][2][3] Company Overview - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology, utilizing its in-house SNÅP platform for drug design [9] - Dabogratinib is the lead candidate from Tyra's pipeline, designed to be a first-in-class oral FGFR3-selective inhibitor, with ongoing clinical trials for both pediatric achondroplasia and cancer [7][9] Clinical Study Details - The BEACH301 study will evaluate dabogratinib in children aged 3 to 10 with achondroplasia, enrolling treatment-naïve participants and those who have received prior therapies [4][5] - The study aims to assess safety, tolerability, and growth velocity changes, with a focus on improving the quality of life for children with achondroplasia [5][6] Market Context - Achondroplasia affects approximately 1 in 15,000 to 40,000 children, with around 250,000 individuals impacted globally, highlighting a significant unmet medical need [2][6] - The FGFR3 G380R mutation is responsible for about 99% of achondroplasia cases, indicating a targeted therapeutic approach could be beneficial [2][6]

Company Overview - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting opportunities in Fibroblast Growth Factor Receptor (FGFR) biology [1] - The company utilizes an in-house precision medicine platform called SNÅP, which enables rapid and precise drug design through iterative molecular SNÅPshots [1] - Tyra has a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions [1] Lead Product and Clinical Development - The lead product, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor designed to avoid toxicities associated with FGFR1, FGFR2, and FGFR4 inhibition [1] - TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer [1] - Other investigational products include TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers [1] Upcoming Event - Company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25, 2025 [2] - The event will feature key management personnel including Todd Harris (CEO), Doug Warner (CMO), and Alan Fuhrman (CFO) [2] - The session is scheduled for 11 am ET and will be hosted by Ellie Merle, a US SMID Cap Biotechnology Analyst at UBS [2]

Group 1 - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology [4] - The company announced that a late-breaking abstract for TYRA-300 has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025) [1] - TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for cancer and skeletal dysplasia, with interim clinical proof-of-concept results in metastatic urothelial cancer [2][4] Group 2 - The planned clinical development for TYRA-300 includes three Phase 2 clinical trials: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer [2][4] - Tyra Biosciences utilizes its in-house SNÅP platform for rapid and precise drug design, which helps predict genetic alterations that may cause resistance to existing therapies [4] - The company is also developing additional investigational drugs, including TYRA-200 and TYRA-430, targeting various FGFR-related cancers [4]